Partnering

We are committed to building the next generation of highly targeted antibody therapeutics.

As part of our value-creation strategy, the company actively seeks strategic partnerships to broaden the application of our platform and advance high-potential product candidates. We are also actively seeking potential collaboration or licensing opportunities that would complement our existing portfolio. We are interested in building alliances that will enable us to realize our long-term vision of transforming lives with safer, more effective therapies.

If you are interested in partnering with us, please contact Debanjan Ray, Chief Financial Officer and Head of Corporate Development at CytomX.

AbbVie

In 2016, CytomX entered into a strategic collaboration with AbbVie Inc. to co-develop and co-commercialize Probody™ Drug Conjugates. Under the terms of the agreement, CytomX and AbbVie™ will co-develop a Probody drug conjugate against CD71, with CytomX leading pre-clinical and early clinical development. AbbVie will lead later development and commercialization, with global late-stage development costs shared between the two companies. AbbVie will lead global commercial activities with CytomX eligible to receive a profit share in the U.S. and tiered double-digit royalties on net product sales outside of the U.S. CytomX retains an option to co-promote in the U.S. AbbVie also receives exclusive worldwide rights to develop and commercialize Probody Drug Conjugates against up to two additional, undisclosed oncology targets.

CytomX

Bristol-Myers Squibb

In March 2017, CytomX and Bristol-Myers Squibb expanded their 2014 worldwide collaboration to discover, develop and commercialize novel therapies using CytomX‘s proprietary Probody(tm) Platform. The collaboration now provides for the selection of up to ten oncology targets and two non-oncology targets. Bristol-Myers Squibb selected all four oncology targets under the original 2014 collaboration, including CTLA-4, the target of Yervoy® (ipilimumab). Bristol-Myers Squibb has progressed its CTLA-4 Probody therapeutic candidate to Investigational New Drug-enabling studies and three additional programs into lead discovery and optimization. Existing targets in CytomX discovery, preclinical research or clinical development are not eligible for selection by Bristol-Myers Squibb, and CytomX’s CX-072, CX-2009, and CX-188 programs remain wholly-owned.

CytomX

ImmunoGen

In January 2014, CytomX entered into a multi-year, strategic collaboration with ImmunoGen, Inc.™ to develop PDCs for the treatment of cancer. Under the terms of the agreement, the companies will collaborate to develop PDCs against a defined number of targets. Each company retains full development control of PDC compounds resulting from our target selection and is responsible for preclinical and clinical testing, manufacturing and commercialization.

CytomX

MD Anderson

In November 2015, CytomX entered into a collaboration with The University of Texas MD Anderson Cancer Center™ to research Probody-enabled chimeric antigen receptor natural killer (ProCAR-NK) cell therapies. Designed for more precise binding to tumors and reduced binding to healthy tissue, ProCAR-NK cell therapies will be created against targets for which safety and toxicity have traditionally been limiting factors for CAR cell therapies. The parties will develop ProCAR-NK cell therapies against multiple undisclosed targets, and CytomX will have the option to license therapeutics that demonstrate preclinical proof of concept for clinical and commercial development.

CytomX

Pfizer

In June 2013, CytomX entered into a global strategic collaboration with Pfizer Inc.™ to develop and commercialize multiple Probody drug conjugates (PDCs) in oncology. Under the terms of the agreement, Pfizer has exclusive rights to pursue development and commercialization of select PDCs. The companies will work together on preclinical research, and Pfizer will be responsible for development and potential commercialization of any selected PDCs.

CytomX

If you are interested in partnering with us, please contact Debanjan Ray, Chief Financial Officer and Head of Corporate Development at CytomX.